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rDescription of evidence collection method
We  conducted  searches  in  multiple  databases  (Medline
1965-2012; Cochrane  Library,  Lilacs)  and  cross-references
with the  collected  material  to  identify  studies  with  better
methodological design,  followed  by  a  critical  evaluation  of
their contents  and  classiﬁcation  according  to  the  strength
of evidence.
We conducted  searches  between  August  and  December
2012. The  following  strategies  were  used  for  searches  in
PubMed:
1. ‘‘regional  anaesthesia’’  OR  ‘‘anesthesia,  conduction’’
OR ‘‘anesthesia’’  AND  ‘‘conduction’’  OR  ‘‘conduction
anesthesia’’ OR  ‘‘regional’’  AND  ‘‘anesthesia’’  OR
‘‘regional  anesthesia’’  AND  ‘‘antithrombotic’’;
2. ‘‘regional  anaesthesia’’  OR  ‘‘anesthesia,  conduc-
tion’’ [MeSH  Terms]  AND  ‘‘infection’’  [MeSH
Terms] AND  ‘‘thromboembolism’’  [MeSH  Terms]  OR
‘‘thromboembolism’’  [All  Fields];
3. ‘‘thromboembolism’’  [MeSH  Terms]  OR
‘‘thromboembolism’’ [All  Fields]  AND  ‘‘regional  anaes-
thesia’’  [All  Fields]  OR  ‘‘anesthesia,  conduction’’  [MeSH
Terms]  OR  ‘‘anesthesia’’  [All  Fields]  AND  ‘‘conduction’’
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http://dx.doi.org/10.1016/j.bjane.2013.04.010[All  Fields])  OR  ‘‘conduction  anesthesia’’  [All  Fields]  OR
‘‘regional’’  [All  Fields]  AND  ‘‘anesthesia’’  [All  Fields]
OR  ‘‘regional  anesthesia’’  [All  Fields].
In  the  ﬁeld  of  regional  anesthesia,  we  selected  stud-
es addressing  managements  of  different  types  of  regional
nesthesia in  individuals  taking  drugs  that  modify  the  blood
oagulation status.  We  focused  on  risk  factors,  etiology,  pre-
ention, diagnosis,  and  treatment.  We  also  included  studies
ssessing the  risk  of  complications  in  patients  after  regional
lockade and  studies  that  clarify  the  management  and  safe
andling of  drugs  to  be  administered.
evel of evidence and strength of
ecommendation
A:  Experimental  or  observational  studies  with  better  con-
sistency.
B:  Experimental  or  observational  studies  with  less  consis-
tency.
C:  Case  reports  or  case  series  (non-controlled  studies).
D:  Opinion  without  critical  evaluation,  based  on  consensus,
expert  opinions,  physiological  studies,  or  animal  models.bjective
o  assess  the  safety  aspects  of  regional  anesthesia  and
nalgesia, such  as  the  possible  technique’s  complications;
lsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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isk  factors  associated  with  spinal  hematoma,  prevention
trategies, diagnosis,  and  treatment;  and  safe  interval  for
rug suspension  and  resumption  after  regional  block  in
atients taking  antithrombotic  drugs.
ntroduction
he  current  incidence  of  neurological  dysfunction  resulting
rom bleeding  complications  associated  with  neuraxial  block
s unknown.1 Its  occurrence  is  estimated  to  be  less  than
:150,000 epidural  punctures  and  1:220,000  subarachnoid
unctures.1 After  neuraxial  anesthesia,  the  use  of  anti-
oagulants is  the  risk  factor  most  often  associated  with
pinal hematoma.2 Because  spinal  hematoma  is  rare,  recom-
endations regarding  regional  anesthesia  and  concomitant
se of  thromboprophylaxis  or  antithrombotic  therapy,  which
ould be  of  greater  predictive  value  if  reported  by  prospec-
ive randomized  studies,  are  based  on  case  reports  and
xpert recommendations3,  which  ethically  precludes  the
tudy.
The number  of  patients  on  anticoagulant  therapy  has
een growing  due  to  the  aging  process,  longer  life
xpectancy, and  prevalence  of  cardiovascular  disease.
ecommendations on  safety  in  regional  anesthesia  and
ntithrombotic therapy  should  be  constantly  updated,  as  the
ntroduction of  new  antithrombotic  drugs  to  the  market  is
one at  regular  intervals.2
This  guideline  aims  to  review  the  risks  and  recommenda-
ions for  regional  anesthesia  in  subjects  taking  drugs  that
nterfere with  coagulation  and  present  safety  regulations
nd guidelines  required  for  regional  procedures.
pinal/epidural hematoma
ncidence
lthough  the  incidence  of  spinal-epidural  hematoma  (SEH)
s small,  the  clinical  severity  of  its  consequences,  along  with
itigation costs  that  follow  an  adverse  event,  makes  it  crucial
o develop  sound  strategies  for  the  management  of  patients
n anticoagulants  during  neuraxial  anesthesia.4
In  a  literature  review5 assessing  several  case  reports,  we
oted that  the  incidence  of  SEH  was  1:220,000  after  spinal
nesthesia and  1:150,000  after  epidural  puncture.  However,
ecent indications  suggest  a  higher  incidence,  as  the  stud-
es used  in  these  calculations  were  conducted  before  the
erioperative thromboprophylaxis  routine.6
After  the  introduction  of  enoxaparin  (30  mg,  twice  daily)
or thromboprophylaxis  in  the  United  States,  an  alarming
umber of  cases  of  epidural  hematoma,  some  with  perma-
ent paraplegia,  the  risk  of  spinal/epidural  hematoma  with
wice daily  administration  of  enoxaparin  was  reported  and
alculated at  1:40,800  after  spinal  anesthesia,  1:6,600  after
imple epidural  puncture,  and  1:3,100  after  epidural  punc-
ure with  epidural  catheter  insertion.7 In  Europe,  a  single
ose administration  of  enoxaparin  (40  mg)  showed  a  lower
ncidence of  spinal  hematoma.  In  a  retrospective  Swedish
tudy,8 the  authors  found  a  risk  of  1:156,000  after  spinal
nesthesia and  1:18,000  in  epidural  anesthesia.  Bleeding
as rare  in  the  obstetric  population  (1:200,000)  compared
ith that  of  women  undergoing  knee  arthroplasty  (1:3,600).
m
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ubsequent  studies  showed  incidences  as  high  as  1:2,700
o 1:19,505.9--11 However,  Cook  et  al.  presented  updated
esults at  the  Third  National  Audit  Project  of  the  Royal  Col-
ege of  Anaesthetists  in  which  only  eight  cases  of  SEH  were
een in  707,405  neuraxial  blocks.  Of  these,  only  ﬁve  met
he inclusion  criteria,  and  the  incidence  was  calculated  at
:88,000 to  1:140,000.12
isk  Factors2,4
he  occurrence  of  SEH  is  more  spontaneous  than  the  result
f neuraxial  anesthesia.  Most  spontaneous  hematomas  are
diopathic; cases  related  to  anticoagulant  therapy  and  vas-
ular  malformations  are  the  second  and  third  most  common
auses, respectively.  Concomitant  use  of  anticoagulants  is
he main  risk  factor  related  to  SEH,  when  associated  with
euraxial block.2
Risk  factors  for  SEH  have  been  described  by  several
uthors8,13--18 and  are  shown  in  Table  1.  The  incidence  of
EH varies  according  to  the  type  of  surgery,  age  and  gender
f patient.  For  example,  the  incidence  of  SEH  in  obstet-
ic surgery  is  estimated  at  1:200,000,  whereas  in  geriatric
ge women  undergoing  knee  arthroplasty  it  is  estimated  at
:3,600.8 This  may  be  explained  by  the  higher  incidence
f spinal  abnormalities  associated  with  osteoporosis,  use  of
ual antiplatelet/anticoagulant  therapy,  and  accumulation
f anticoagulant  due  to  a  decrease  in  renal  excretion  not
etected in  this  age  group.
Among  the  type  of  neuraxial  blocks,  the  risk  of  SEH  is
igher with  the  use  of  epidural  catheters,  followed  by  simple
pidural puncture,  and  less  frequent  after  single  subarach-
oid puncture,17,19,20 the  latter  likely  due  to  the  thinner
eedles used  in  the  technique.  Catheter  removal  is  as  crit-
cal as  insertion;  therefore,  vascular  injury  may  still  occur4
t  the  same  incidence;  that  is,  half  the  cases  of  SEH  occurs
uring epidural  catheter  removal.16
There  are  indications  that  epidural  hematoma  is  more
ommon after  lumbar  puncture  compared  with  thoracic
uncture.11
linical  condition,  treatment,  and  prevention
leeding  into  the  spinal  canal,  which  causes  thecal  sac
ompression, may  result  in  irreversible  neurological  damage
ith paraplegia  and  is  a  major  concern  of  anesthesiolo-
ists performing  neuraxial  block  in  patients  on  anticoagulant
rugs.4
Clinical  condition  is  characterized  by  slow  regression  or
bsent sensory  or  motor  block,  back  pain,  urinary  reten-
ion or  return  of  motor  or  sensory  deﬁcit  after  complete
egression of  the  previous  block,  alone  or  in  combination,
uggesting the  development  of  spinal  hematoma.2
In  the  presence  of  clinical  suspicion  of  spinal  hematoma,
n aggressive  diagnostic  and  therapeutic  approach  is  manda-
ory. This  includes  emergency  nuclear  magnetic  resonance
maging (NMRI)  or,  if  unavailable,  computed  tomography
CT). Because  SEH  is  a  neurosurgical  emergency,  protocols
ust be  established  to  avoid  any  delay  in  diagnosis.  Once
iagnosis is  conﬁrmed,  decompressive  laminectomy  should
e performed  within  6-12  hours  after  the  onset  of  symptoms,
nabling chances  of  neurological  recovery.16,21
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Table  1  Risk  Factors  Associated  with  Hematoma  Spinal/Epidural.
1  -- Patient-related
a.  Age  (elderly);
b. Female;
c. Congenital  coagulopathies;
d. Acquired  coagulopathies  (renal/hepatic  malignancies,  HELLP  syndrome  (hemolysis,  elevated  liver  enzymes,  low  platelet
count), disseminated  intravascular  coagulation  [DIC]);
e.  Thrombocytopenia;
f. Spinal  abnormalities  (spina  biﬁ  da/spinal  stenosis,  osteoporosis,  ankylosing  spondylitis).
2  -- Procedure-related
a.  Insertion  or  removal  of  the  catheter;
b.  Traumatic  procedure  (multiple  attempts);
c.  Presence  of  blood  in  the  catheter  during  insertion  or  removal;
d. Epidural  catheter  insertion  >  Simple  epidural  puncture  >  Simple  spinal  puncture.
3 -- Drug-related
a.  Anticoagulant  drugs,  antiplatelet  or  ﬁ  brinolytic;
b.  Administration  of  the  drug  immediately  before/after  neuraxial  technique;
c. Use  of  antiplatelet  therapy/dual  anticoagulant.
Drugs  Recommendations
ASA  and  NSAIDs  There  is  no  indication  of  suspension.
ASA and  NSAIDs  +
LMWH/UFH/coumarin
Wait 24  hours  for  neuraxial  block  or  epidural  catheter  insertion.
ASA +  thienopyridine  If  the  patient  is  using  metallic  stent,  wait  6  weeks.  If  the  stent  is  pharmacological,  wait  6  months.
Ticlopidine  Perform  blockade  or  insertion/removal  of  catheter  10-14  days  after  suspension.
Clopidogrel Perform  blockade  or  insertion/removal  of  catheter  7  days  after
suspension.  In  high  risk  patients,  it  may  be  performed  in  5  days.
Prasugrel  Perform  neuraxial  block  7-10  days  after  drug  discontinuation.
Abciximab  Perform  neuraxial  block  or  insertion/removal  of  catheter  48  hours  after  drug  discontinuation.
Tiroﬁ ban/eptiﬁbatide  Wait  8-10  hours  to  perform  neuraxial  block  or  epidural  catheter  insertion.
Glycoprotein  IIb/IIIa  inhibitors
+ other  anticoagulants/AAS
Contraindication  for  blockade.
Ticagrelor Perform blockade  or  insertion/removal  of  catheter  5  days  after  drug  discontinuation.
Cilostazol Perform  blockade  or  insertion/removal  of  catheter  5  days  after  drug  discontinuation.
Unfractionated heparin Wait  4  hours  after  the  last  dose  of  UFH  for  blockade,  removal/insertion  of  catheter.  Restart  drug  after  1  hour.
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Table  1  (Continued  )
Drugs  Recommendations
Low  molecular  weight  heparin  Prophylactic  doses:  wait  10-12  hours  to  perform  blockade.
Therapeutic  doses:  wait  24  hours.  Withdrawal  of  catheter  10-12
hours  after  last  dose.  Restart  drug  2  hours  after  catheter  removal.
Coumarin  Perform  blockade  4-5  days  after  discontinuation.  INR  monitoring
during epidural  analgesia.
Fondaparinux Prophylactic  dose  (2.5  mg):  blockade  may  be  performed.  If  epidural
catheter, remove  it  36  hours  after  the  last  dose.  Restart  dose  12
hours  after  catheter  removal.  Therapeutic  dose  (5-10  mg):  blockade  is  contraindicated.
Rivaroxaban Perform  neuraxial  blockade,  insertion/removal  of  catheter  24  hours
after  drug  discontinuation.  Restart  4-6  hours  after  catheter  removal.
Apixaban  Perform  neuraxial  blockade,  insertion/removal  of  catheter  20-30
hours after  drug  discontinuation.  Restart  4-6  hours  after  catheter  removal.
Desirudin  Perform  blockade  8-10  hours  after  drug  discontinuation  in  patients  with  normal  renal  function.
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2SBA  Recommendations  for  regional  anesthesia  safety  in  pati
Thus,  patients  should  be  carefully  evaluated  to  investi-
gate possible  signs  indicating  SEH,  both  after  neuraxial  block
and epidural  catheter  removal.  The  patient  should  be  mon-
itored at  regular  intervals  until  regression  of  sensory  block
by at  least  two  dermatomes  or  motor  function  recovery2 and
for at  least  24  hours  after  epidural  catheter  removal.21
European  and  American  societies  have  published  guide-
lines with  the  goal  of  increasing  security  in  performing
neuraxial block  in  patients  on  anticoagulants.1,6,22--27 How-
ever, most  of  these  recommendations  are  expert  opinions
based on  case  series  and  pharmacological  data  with
anticoagulant drugs  involved.27 These  recommendations
include: (I)  minimum  time  interval  required  between  the
last dose  of  anticoagulant  and  the  insertion  of  neurax-
ial needle/catheter  or  catheter  removal;  (II)  minimum
interval required  between  the  insertion  of  neuraxial
needle/catheter  or  catheter  removal  and  next  dose  of  anti-
coagulant; (III)  minimum  coagulation  time  required  for  the
use of  neuraxial  technique  (if  available  for  the  drug  being
used).
Due to  the  rapid  development  of  anticoagulant  drugs  by
the pharmaceutical  industry  and  their  release  and  increas-
ing use  in  clinical  practice,  experiments  are  lacking  and
it becomes  difﬁcult  to  make  any  statement  on  the  use  of
neuraxial anesthesia  in  patients  on  new  anticoagulants.
Recently,  Rosencher  et  al.  proposed  a  new  strategy  for
managing patients  on  new  anticoagulants.28 According  to
this strategy,  the  insertion  and  subsequent  withdrawal  of
neuraxial needle/catheter  must  be  made  at  a  time  superior
to two  half-lives  of  elimination  after  the  last  dose  of  the
used anticoagulant.  The  basis  for  this  proposal  is  that  30%
to 40%  of  the  function  of  coagulation  factors  is  required  for
hemostasis, so  that  after  two  half-lives,  the  drug  concen-
tration in  bloodstream  is  near  25%  of  the  initial.  The  next
anticoagulant dose  should  be  administered  with  a  time  inter-
val  (dT)  obtained  by  subtracting  the  time  needed  for  the
drug to  reach  the  peak  plasma  level  and  the  time  to  produce
stable blood  clot,  considered  8  hours  (8h-Tpeak =  dT).28
Neuraxial  block  and  use  of  antiplatelet  agents
Antiplatelet  drugs  consist  of  non-steroidal  anti-
inﬂammatory drugs  (NSAIDs),  thienopyridines  (ticlopidine,
clopidogrel, and  prasugrel),  and  glycoprotein  IIb/IIIa
inhibitors (abciximab,  eptiﬁbatide,  and  tiroﬁban).
Acetylsalicylic  acid  (ASA)  and  NSAIDs
ASA  promotes  irreversible  blockade  of  platelet  function  by
inhibiting cyclooxygenase  enzyme  production  of  thrombox-
ane A2 (potent  platelet  activator).  This  effect  lasts  the  same
as the  platelets’  half-life,  usually  7-10  days.3
Other  NSAIDs  also  inhibit  cyclooxygenase-1  and  platelet
aggregation, but  in  a  reversible  manner  and  proportional
to the  agent  half-life.  This  process  normalizes  from  12
to 24  hours  after  NSAIDs  discontinuation.29 The  selective
inhibitors of  Type  2  cyclooxygenase  (COX-2)  are  anti-
inﬂammatory drugs  that  do  not  cause  platelet  dysfunction,
as COX-2  is  not  expressed  in  platelets.30
The  bleeding  effect  caused  by  ASA  appears  to  be  dose-
dependent, with  more  marked  effects  in  patients  receiving
3taking  anticoagulants  5
oses  greater  than  100  mg.day-1 31 However,  prospective
tudies evaluating  the  safety  of  neuraxial  block  with  ASA
eported no  case  of  spinal  hematoma.32--34
Although  the  isolated  use  of  ASA  seems  not  to  increase
he probability  of  spinal  hematoma,  complications  have
een observed  in  both  medical  and  surgical  patients,  if
ombined with  heparin.14,35 Thus,  in  individuals  using  ASA,
t seems  prudent  to  administer  heparin  for  postopera-
ive thrombosis  prophylaxis,  as  the  research  team  did  not
bserve superiority  of  thromboprophylaxis  when  the  heparin
ose is  given  preoperatively  (B).36 However,  the  administra-
ion of  a low-dose  combination  of  ASA-dipyridamole  seems
ot to  increase  the  risk  of  spinal  hematoma.2
In  patients  with  a  history  of  acute  coronary  syndrome
ACS), cerebrovascular  accident  (CVA)  or  peripheral  arterial
cclusive disease,  ASA  reduces  the  risk  of  recurrent  car-
iovascular events  by  30%  and  mortality  by  approximately
5%.37 Recent  studies  suggest  that  morbidity  and  mortal-
ty, particularly  in  patients  with  newly  implanted  coronary
tents or  unstable  coronary  syndrome  is  markedly  increased
f ASA  is  suspended  before  a  surgical  procedure.38--40
ebound  phenomenon  has  also  been  described.41 The  risk
f late  thrombosis  is  higher  in  patients  with  drug-eluting
tents.
In summary,  the  perioperative  suspension  of  ASA  is  unnec-
ssary in  most  cases  and  associated  with  an  increased  risk
f acute  thrombosis.  We  recommend  that  patients  with
CS or  stent  should  continue  taking  ASA  throughout  life.42
he  American  College  of  Chest  Physicians  (ACCP)  does  not
ecommend platelet  function  evaluation  prior  to  invasive
rocedures because  there  is  no  apparent  correlation  with
leeding (D).43
ecommendations
.  NSAIDs  appear  to  represent  no  signiﬁcant  additional  risk
for  the  onset  of  spinal  hematoma  in  patients  undergo-
ing epidural  or  spinal  anesthesia.  NSAIDs  (including  ASA)
have  no  risk  level  that  interferes  with  the  performance  of
neuraxial  blocks.  In  patients  on  these  medications,  there
is  no  speciﬁc  concern  regarding  the  interval  between
spinal/epidural puncture  or  catheter  insertion  and  the
last  dose  of  the  given  drug,  or  the  need  for  postoperative
monitoring  and  interval  for  catheter  removal  or  postop-
erative  drug  administration  (A).6,32--34
.  Concomitant  use  of  medications  affecting  other  clot-
ting  mechanism  components,  such  as  oral  anticoagu-
lants, unfractionated  or  low  molecular  weight  heparin
increases  the  risk  of  bleeding  complications  in  patients
on  NSAIDs.  In  these  patients  on  ASA,  the  administration  of
heparin  dosage  for  postoperative  thromboprophylaxis  is
recommended  (B).36 In  these  patients,  if  low  molecular
weight heparin  (LMWH)  is  administered  preoperatively,
there should  be  a  24-hour  wait  period  before  performing
blockade or  removing  the  epidural  catheter  due  to  the
increased  risk  of  bleeding  (C).6.  Cyclooxygenase  Type  2  inhibitors  (COX-2)  have  mini-
mal  effect  on  platelet  function  and  should  be  preferred
in  patients  who  need  anti-inﬂammatory  therapy  in  the
presence  of  anticoagulation  (D).6 There  is  no  evidence
64
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supporting  the  effect  on  the  ability  of  platelet  aggrega-
tion or  increased  tendency  to  bleeding  (D).1
.  In  patients  with  coronary  stent  receiving  dual  platelet
therapy (ASA  +  thienopyridine),  needing  surgery,  and
requiring  surgical  procedure,  we  recommend  postpon-
ing  surgery  for  at  least  6  weeks  in  the  case  of  metallic
stents and  at  least  6  months  in  case  of  drug-eluting
stents (D).43 If  patients  need  surgery  within  6  weeks  after
metallic  stent  or  6  months  after  drug-eluting  stent,  dual
antiplatelet  therapy  should  be  maintained,  and  regional
anesthesia  is  contraindicated  via  neuraxial  route  (D).43
.  Analgesics,  such  as  paracetamol  and  dipyrone,  are  not  a
contraindication  for  neuraxial  regional  anesthesia,  inso-
far  there  are  no  cases  related  to  spinal  hematoma  (D).3
hienopyridines
iclopidine  (Ticlid®),  clopidogrel  (Plavix®),  and  prasugrel
Eﬁent®) are  platelet  inhibitors  belonging  to  the  class  of
hienopyridines. They  are  prodrugs  cleaved  in  vivo  in  the
iver to  active  metabolites  that  antagonize  the  platelet
eceptor of  adenosine  dinucleotide  phosphate  (ADP)  (P2Y12)
nd interfere  with  platelet  activation  and  aggregation,  an
ffect that  can  not  be  antagonized  and  is  irreversible.1,2
There  is  no  prospective  study  assessing  the  safety  of
euraxial techniques  in  subjects  under  treatment  with
hienopyridines. However,  cases  of  spinal  hematoma  have
een reported  after  neuraxial  anesthesia  in  patients  taking
hese drugs.44
iclopidine (Ticlid®)
iclopidine  half-life  is  30  to  50  hours,  which  increases  up  to
6 hours  if  used  routinely  for  more  than  14  days.2 Platelet
ysfunction with  the  use  of  ticlopidine  remains  for  10  to  14
ays after  drug  discontinuation.1 Unlike  clopidogrel,  ticlo-
idine may  lead  to  neutropenia  in  more  than  1%  of  patients,
hich is  a  limiting  factor  of  its  use.3
ecommendations
euraxial  block  or  epidural  catheter  removal  can  only  be
erformed after  10-14  days  of  ticlopidine  suspension  (D).3,6
lopidogrel (Plavix®)
lopidogrel  half-life  is  120  hours.  However,  its  active
etabolite half-life  is  only  8  hours.2 The  platelet  function
aximum inhibition  of  oral  clopidogrel  (75  mg)  occurs  within
-7 days  or  about  12-24  hours  after  an  initial  loading  dose
f 300-600  mg.  Recovery  of  platelet  function  occurs  only
-7 days  after  the  end  of  clopidogrel  administration.45 In
atients at  high  risk  for  angina,  discontinuation  for  ﬁve  days
as been  suggested  to  prevent  cardiovascular  morbidity.46
ecommendationseuraxial  blockade  or  removal  of  epidural  catheter  in
atients on  clopidogrel  should  only  be  performed  after  at
east seven  days  of  drug  discontinuation  (D).3 In  the  case  ofN.M.  Fonseca  et  al.
atients  with  high  risk  of  angina  recurrence,  the  interval  of
ve days  suspension  has  been  suggested  (D).6
rasugrel (Eﬁent®)
 novel  thienopyridine  that,  similar  to  others,  depends  on
epatic conversion  to  active  metabolite  to  bind  to  platelet
2Y12 receptor  (which  binds  to  ADP  for  platelet  activation)
nd perform  its  inhibitory  activity.  This  drug  has  a  rapid
nset of  action  (30-60  minutes)  and  is  10  times  more  potent
han clopidogrel.47 The  antiplatelet  effect  is  equal  to  the  life
f platelet,  and  pretreatment  platelet  function  is  restored
-10 days  after  drug  discontinuation.3
One  study  comparing  prasugrel  and  clopidogrel  in  13,608
atients with  acute  coronary  syndrome  undergoing  percu-
aneous coronary  intervention  showed  signiﬁcant  reduction
f ischemic  events  treated  with  prasugrel,  but  also  a  higher
nd occasionally  fatal  risk  of  bleeding.48
ecommendations
here  is  no  available  study  assessing  the  combination  of
rasugrel and  neuraxial  anesthesia.  However,  it  seems  rea-
onable that  treatment  with  prasugrel  be  discontinued  at
east 7-10  days  before  neuraxial  block  or  removal  of  epidural
atheter (D).3
lycoprotein IIb/IIIa inhibitors
lycoprotein  IIb/IIIa  inhibitors  include  abciximab
Reopro®), eptiﬁbatide  (Integrilin®),  and  tiroﬁban
Aggrastat®). Currently,  these  agents  are  the  most
ffective drugs  available  for  platelet  aggregation  inhibi-
ion, as  they  block  the  platelet  glycoprotein  IIb/IIIa  (the
ite of  ﬁbrinogen  binding  between  platelets),  which  is  the
nal common  pathway  of  platelet  aggregation.2 These  drugs
re only  available  for  intravenous  use.  Antiplatelet  effects
re reversible  and  disappear  after  the  discontinuation  of
ptiﬁbatide, tiroﬁban,  and  abciximab  within  8,  24,  and
8 hours,  respectively.  The  most  common  side  effects  are
hrombocytopenia and  bleeding,50 expressed  in  0.3-1%
ith abciximab.49 Abciximab  showed  better  efﬁcacy  than
iroﬁban and  eptiﬁbatide.51
ecommendations
.  According  to  the  pharmacological  properties  of  these
drugs,  insertion  of  epidural/spinal  needle/catheter  or
catheter  removal  should  only  be  performed  after  com-
plete  recovery  of  platelet  aggregation;  that  is,  with
discontinuation  of  8-10  hours  for  tiroﬁban/eptiﬁbatide
and 48  hours  for  abciximab  and  exclusion  of  any  throm-
bocytopenia  through  a  recent  platelet  count  (D);2
.  GP  IIb/IIIa  inhibitors  are  used  in  acute  coronary  syn-
drome,  in  combination  with  anticoagulants  and  ASA.  In
this  scenario,  any  neuraxial  blockade  is  contraindicated
in emergency  procedures  that  usually  involve  cardiac
surgery  with  continued  anticoagulation  (D).3
ents  
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Other antiplatelet
Ticagrelor  (Brilinta®)
Unlike  thienopyridines,  ticagrelor  acts  directly  on  P2Y12
receptor and  does  not  require  liver  biotransformation  into
active metabolites  by  cytochrome  P450,  although  metabo-
lites are  also  active.  Similar  to  prasugrel,  ticagrelor  provides
a very  fast  (<  2  h),  intense  (about  70%),  and  consistent
inhibition of  P2Y12  receptor,  which  is  greater  than  that
of clopidogrel  (30-40%).47 It  has  a  rapid  onset  of  action
with reversible  binding  and  short  duration  (48-72  h),  and
requires oral  administration  in  two  doses.  The  initial  effect
on platelet  aggregation  is  seen  30  minutes  after  loading
dose. With  treatment  discontinuation,  platelet  function  is
restored within  4-5  days.52
Recommendations
There  is  no  available  data  regarding  the  perioperative
use of  this  agent.  Theoretically,  its  short  and  reversible
antiplatelet effect  can  facilitate  perioperative  manage-
ment. However,  neuraxial  anesthesia  should  be  discouraged
during treatment  with  ticagrelor,  unless  it  is  suspended  for
at least  ﬁve  days  before  the  anesthetic  procedure,  so  that
platelet function  can  return  to  normal  (D).3
Cilostazol (Vasogard®, Cebralat®, Pletal®)
Cilostazol  provides  selective  inhibition  of  phosphodiesterase
IIIa (PDEIIIa);  thus,  it  increases  the  level  of  intracellu-
lar cyclic  adenosine  monophosphate  (cAMP)  and  leads  to
weak platelet  aggregation  inhibition.53,54 Because  vascu-
lar smooth  muscle  contains  PDEIIIa,  cilostazol  also  provides
direct arterial  vasodilation.  Nevertheless,  cilostazol  mech-
anism of  action  is  not  fully  understood.  Its  use  is  indicated
for peripheral  arterial  disease  and  intermittent  claudication
in individuals  who  do  not  respond  to  exercise  therapy  and
those with  low  possibility  of  surgical  intervention.55
The  route  of  administration  is  orally  at  a  dose  of  100  mg
twice daily,  and  peak  plasma  level  is  achieved  within  2.7  to
3.6 hours.  Drug  compound  is  mainly  eliminated  by  hepatic
metabolism and  subsequent  urinary  excretion  of  metabo-
lites. The  terminal  elimination  half-life  of  cilostazol  and  its
active metabolites  is  approximately  21  hours,  and  some  of  its
metabolites inhibit  platelet  aggregation  at  a  higher  intensity
than the  parent  compound.54
A  recent  case  report  found  spinal  hematoma  after  epidu-
ral catheter  removal  during  treatment  with  cilostazol,56 but,
in general,  there  is  no  prospective  data  on  this  drug’s  periop-
erative use  and  its  effect  on  bleeding  incidence  is  unknown.
Recommendations
Neuraxial  block  and  catheter  removal  may  be  performed
considering the  minimum  clearance  interval  of  two  half-
lives between  blockade  and  the  last  dose  of  cilostazol  (i.e.,
42 hours),  although  laboratory  recommendation  is  ﬁve  days
of suspension.3 The  next  dose  of  cilostazol  should  only  be
administered 5  hours  after  catheter  removal  (D).28,57
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eparins
nfractionated  heparin  (UFH)
he  major  anticoagulant  effect  of  heparin  is  due  to  pen-
asaccharide present  in  one  third  of  heparin  molecules,
hich binds  to  antithrombin  III  (ATIII).6 After  this  binding,
FH catalyses  the  inactivation  of  IIa  (thrombin),  IXa,  and  Xa,
nd, to  a  lesser  extent,  XIa  and  XIIa  factors.4 In  the  absence
f heparin,  antithrombin  III  has  low  afﬁnity  for  thrombin.
owever, when  UFH  binds  to  ATIII,  the  thrombin-binding
ate accelerates  from  100  to  1,000  times,  similarly  to  other
oagulation factors  inhibited  by  it.  UFH  also  binds  strongly
o several  plasma  proteins,  endothelial  cells,  macrophages,
nd platelet  factor  4  (PF4),  which  results  in  low  bioavail-
bility, inaccurate  pharmacokinetics,  and  heparin-induced
hrombocytopenia  (HIT).58
The  anticoagulant  activity  of  UFH  depends  on  both  the
umber of  heparin  molecules  with  the  pentasaccharide
hain in  its  composition  and  the  size  of  molecules  containing
he pentasaccharide.  The  high  molecular  weight  heparins
ill catalyze  the  inhibition  of  Xa  and  IIa  factors,  while
he low  molecular  weight  heparins  will  only  inhibit  the  Xa
actor.58,59
Intravenous  administration  of  UFH  results  in  immediate
nticoagulation, while  subcutaneous  administration  results
n onset  of  action  within  1-2  hours.  The  anticoagulant  effect
s both  molecular  weight  and  dose  dependent,  in  a nonlin-
ar manner,  and  increases  disproportionately  with  increased
ose.6 The  biological  half-life  of  heparin  increases  from
0 minutes  with  25  UI.kg-1 IV  to  60  minutes  with  100  UI.kg-1
nd  to  150  minutes  with  400  UI.kg-1.59
When  given  in  therapeutic  doses,  UFH  anticoagulation
s monitored  by  the  activated  partial  thromboplastin  time
aPTT). During  cardiopulmonary  bypass,  coagulation  inhibi-
ion  by  high  doses  of  heparin  is  monitored  by  the  activated
lotting time  (ACT).  Subcutaneous  administration  of  small
oses (5,000  IU)  for  prophylaxis  of  deep  venous  thrombo-
is (DVT)  usually  does  not  change  the  aPTT.  One  of  the
dvantages of  heparin  anticoagulation  is  the  reversal  by  pro-
amine. Each  milligram  of  protamine  can  neutralize  100  IU
f heparin.58
A  review  study  of  more  than  9,000  patients  undergo-
ng neuraxial  block  with  prophylactic  doses  for  DVT  with
eparin showed  no  cases  of  spinal  hematoma.60 However,
solated cases  have  been  reported  subsequently  to  that
evision.9,16,10,61--63 In  patients  receiving  two-  daily  dose
egimen of  subcutaneous  UFH  (5,000  IU)  there  is  no  con-
raindication for  the  use  of  neuraxial  techniques.6 However,
here are  insufﬁcient  data  to  conﬁrm  the  safety  of  neurax-
al techniques  with  three  daily  doses,  despite  being  the  most
ffective  dosage  for  DVT  prevention.64
In  contrast  to  UFH  prophylactic  regimen,  anticoagulation
herapy is  deﬁnitely  associated  with  increased  risk  of  spinal
ematoma4.  A  prospective  study  (n  =  342)  comparing  the
ncidence of  spinal  hematoma  in  patients  with  and  without
herapeutic doses  of  UFH  and  undergoing  lumbar  puncture
howed incidence  of  2%  in  the  UFH  group.  The  risk  factors
ere: (i)  less  than  1  hour  interval  between  the  onset  of  hep-
rin and  lumbar  puncture;  (ii)  concomitant  use  of  ASA  at  the
ime of  lumbar  puncture;  and  (iii)  traumatic  procedure.14
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ecently,  two  cases  of  epidural  hematoma  were  reported
ssociated with  UFH  therapy  and  neuraxial  block.65,66
Heparinization  during  surgery  involves  the  use  of  5,000
o 10,000  U  of  heparin  intravenously  during  surgery,  par-
icularly in  vascular  surgery  to  prevent  thrombosis  during
rtery clamping.59 Most  published  cases  series  uses  the
ame guidelines  for  neuraxial  anesthesia  management  in
hese patients,  based  on  the  exclusion  of  high-risk  patients
preexisting coagulopathy)  and  performing  the  neuraxial
echnique at  least  one  hour  before  heparin  administration.60
tafford-Smith  showed  increased  incidence  of  bleeding
n patients  on  ASA  associated  with  intraoperative  intra-
enous heparin.  SEH  risk  increased  to  1:8,500  after  epidural
uncture and  to  1:12,000  after  spinal  anesthesia,  even
hen neuraxial  anesthesia  and  subsequent  heparinization
ccurred after  one-hour  interval.35
In  cardiac  surgery,  the  beneﬁts  of  thoracic  epidural  anes-
hesia on  pulmonary  function  and  analgesia  are  evident,
ith lower  intensity  for  arrhythmia  management  and  no
ffect on  hospital  and  ICU  length  of  stay  and  mortality.67,68
owever,  the  beneﬁts  must  be  evaluated  concerning  the
igh risk  of  SEH.  The  probability  of  spinal  hematoma  in
atients undergoing  cardiac  surgery  with  full  hepariniza-
ion is  1:1,528  with  epidural  and  1:3,610  with  spinal
echniques.69,70 Experts  recommend  that  neuraxial  block  be
erformed the  day  before  surgery  due  to  complete  surgical
eparinization.22,71,72 Because  neuraxial  blockade  in  cardiac
urgery carries  signiﬁcant  risks  without  improving  morbidity
nd mortality,  there  is  discussion  whether  epidural  or  spinal
nesthesia is  justiﬁed,  probably  with  the  contraindication  of
he technique  in  this  group.72
ecommendations
.  In  patients  on  two  daily  prophylactic  doses  of  UFH  (5,000
IU)  there  are  no  contraindications  to  neuraxial  block  (D);6
.  The  safety  of  neuraxial  block  in  patients  receiving  pro-
phylactic  doses  of  UFH  above  10,000  IU  or  above  two
daily  doses  is  not  established.  Although  dosage  of  three
daily  doses  may  lead  to  increased  surgical  bleeding,  it
is  unclear  whether  there  is  an  increased  risk  for  spinal
hematoma  development  (D);6
.  Because  heparin-induced  thrombocytopenia  (HIT)  may
occur  during  UFH  administration,  platelet  count  should
be  done  before  neuraxial  technique  or  catheter  removal,
if  the  patient  is  on  HNF  for  ﬁve  or  more  days  (B);3
.  Wait  a  minimum  interval  of  4  hours  between  the  last  pro-
phylactic  dose  of  UFH  and  spinal/epidural  puncture  or
epidural  catheter  removal.  The  next  dose  of  prophylac-
tic UFH  should  be  administered  at  least  one  hour  after
neuraxial  anesthesia  or  epidural  catheter  removal  (D);3
.  If  UFH  is  used  in  therapeutic  doses  to  perform  neurax-
ial anesthesia,  administration  of  continuous  intravenous
heparin  therapy  should  be  discontinued  for  at  least
4 hours  before  puncture  or  catheter  removal,  and  it  is
necessary  to  check  the  return  of  normal  coagulation  by
determining  aPTT  or  ACT  (D);3.  In  situations  of  intraoperative  heparinization,  the  follow-
ing  recommendations  should  be  considered:  1)  minimum
interval  of  one-hour  between  puncture  or  catheter  place-
ment  and  heparinization;  2)  do  not  perform  neuraxial
c
h
d
cN.M.  Fonseca  et  al.
block  in  patients  with  coagulopathy  or  on  anticoagu-
lants; 3)  wait  4  hours  between  the  last  dose  and  epidural
catheter  removal,  preferably  with  laboratory  coagula-
tion  tests;  4)  after  catheter  removal,  wait  one  hour  for
UFH  dose  application;  5)  although  the  occurrence  of  difﬁ-
cult  puncture  or  blood  output  from  puncture  needle  may
increase  the  risk  of  spinal  hematoma,  there  are  no  data
to  justify  surgery  cancellation  (A).6
ow molecular weight heparin (LMWH)
MWH  has  become  the  treatment  of  choice  for  both  preven-
ion and  treatment  of  DVT,  due  to  the  greater  bioavailability
almost 100%)  after  subcutaneous  administration,  which
esults in  higher  anticoagulant  effect  without  increasing
leeding tendency  and  ease  of  use  without  the  need  for
lood coagulation  monitoring.2
Pharmacology  of  LMWH  differs  from  UFH.  The  main  dif-
erences are  the  highest  inhibitory  activity  against  the
a factor  compared  with  thrombin  (IIa),  anticoagulant
ffect difﬁcult  monitoring  (factor  Xa  levels),  prolonged  half-
ife, and  lack  of  complete  reversibility  with  protamine.58
ith  subcutaneous  administration,  peak  plasma  levels  are
eached in  approximately  3-4  hours,  and  the  half-life  of
limination, with  normal  renal  function,  is  within  4-
 hours.73,74 However,  the  anti-factor  Xa  activity  remains
onsiderable (50%)  after  10-12  hours  of  administration.  If
reatinine clearance  falls  below  30  mL.min-1,  the  half-life
oubles.74 Compared  to  UFH,  the  risk  of  thrombocytopenia
HIT) is  10  times  lower.  However,  they  are  contraindicated
n HIT  due  to  the  high  risk  of  cross-reaction,  approximately
0%.75
If  thromboprophylaxis  with  LMWH  is  prescribed  in  two
aily doses  (30  mg),  compared  to  a  daily  dose  regimen,  the
isk of  spinal  hematoma  may  be  increased,  as  the  minimum
evels of  anti-Xa  activity  are  higher.76
The  use  of  LMWH  in  patients  undergoing  neuraxial  block
as adopted  in  Europe  in  1987.  Dosages  used  were  20-40  mg
n a  single  dose  12  hours  before  surgery.  To  prevent  the
ccurrence of  spinal  hematoma,  guidelines  recommended
nsertion/removal of  epidural  catheter  at  a  minimum  inter-
al  of  10-12  hours  after  the  last  dose  of  LMWH.  The
ubsequent dose  was  restarted  after  8-12  hours.5,16 Thus,
eviews involving  data  from  millions  of  patients  showed  that
he use  of  neuraxial  block  in  subjects  on  LMWH  under  the
uropean regime  was  safe,  with  report  of  only  one  case  of
pinal hematoma.77,78
On  the  other  hand,  in  the  United  States,  enoxaparin
ntroduced in  1993  had  no  recommendation  regarding  time
etween drug  administration  and  neuraxial  block  or  catheter
emoval. Enoxaparin  was  routinely  administered  in  the
mmediate postoperative  period  at  a  dose  of  30  mg  twice
aily. After  ﬁve  years  of  use,  the  Food  and  Drug  Administra-
ion (FDA)  accumulated  reports  of  43  patients  undergoing
euraxial blocks  who  developed  spinal  hematoma.79 In  1998,
3 cases  of  spinal  hematoma  associated  with  LMWH  had  been
eported in  Europe,  while  in  United  States,  it  reached  60
ases.24 Reasons  for  the  high  rates  were  attributed  to:  (i)
igher daily  dose  prescription  of  LMWH;  (ii)  more  frequent
oses, possibly  leading  to  higher  minimum  blood  level  during
atheter insertion/removal;  (iii)  lack  of  practical  guidelines
ents  
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for  neuraxial  block  and  LMWH  administration;  (iv)  lack  of
larger series.19,24
After  the  Second  American  Society  of  Regional  Anesthesia
(ASRA) resolution  in  2003,  studies  in  the  English  literature
reported 10  cases  related  to  the  combination  of  LMWH  and
spinal hematoma.  Five  additional  cases  were  reported  by  the
Royal College  of  Anesthetists  Consensus  in  the  UK  in  97,925
epidural blocks,  but  without  proven  evidence  of  association
with anticoagulant  drugs.12
Recommendations
1.  Antiplatelet  drugs  and  oral  anticoagulants  concomitantly
administered  with  LMWH  increase  the  risk  of  spinal
hematoma, and  in  such  conditions  blockade  is  contraindi-
cated.  In  patients  on  ASA,  it  seems  prudent  to  administer
the thromboprophylatic  dose  of  heparin  postoperatively
(B).36 In  these  patients,  if  LMWH  is  administered  preop-
eratively, wait  24  hours  to  perform  blockade  or  catheter
removal  due  to  increased  risk  of  bleeding  (C);6
2.  Bleeding  during  needle  or  catheter  insertion  does  not  jus-
tify  surgery  cancellation.  The  beginning  of  therapy  with
LMWH  in  this  circumstance  should  occur  24  hours  after
the  end  of  surgery  (D);6
3.  In  preoperative  patients  receiving  LMWH  thrombopro-
phylaxis, neuraxial  block  is  recommended  10-12  hours
after  the  last  dose  of  LMWH  (D);6
4.  In  patients  on  therapeutic  doses  of  LMWH,  such  as  enoxa-
parin  1  mg.kg-1 every  12  hours,  enoxaparin  1.5  mg.kg-1
per  day,  dalteparin  120  IU.kg-1 every  12  hours,  dalteparin
200 IU.kg-1 per  day  or  tinzaparin  175  IU.kg-1 per  day,  an
interval  of  at  least  24  hours  is  recommended  between  the
last  dose  and  neuraxial  block  to  ensure  normal  hemosta-
sis  (D);6
5.  Patients  under  prophylactic  regimen  of  LMWH  every
12 hours  (enoxaparin  30  mg  twice  daily),  one  dose  should
be  omitted  to  enable  a  24  hours  interval  before  neuraxial
block or  catheter  removal  (A);3
6.  Regarding  LMWH  postoperative  use,  the  ﬁrst  dose  should
be  administered  6-8  hours  after  surgery.  A  second  dose  of
LMWH  should  not  be  administered  before  24  hours  of  the
ﬁrst  dose.  Thus,  epidural  catheter  may  be  safely  main-
tained.  However,  epidural  catheter  removal  should  only
be  done  after  10-12  hours  of  the  last  dose.  The  subse-
quent dose  of  LMWH  after  catheter  removal  should  be
administered  after  2  hours.  No  drugs  that  alter  hemosta-
sis should  be  given  due  to  the  risk  of  additive  effects
(D);6
7.  In  patients  under  twice  daily  dosage  regimen,  there  is
greater  risk  of  spinal  hematoma,  and  continued  monitor-
ing  is  recommended.  The  ﬁrst  dose  of  LMWH  should  be
administered  24  hours  after  the  end  of  surgery,  regardless
of  the  anesthetic  technique,  and  only  in  the  presence  of
adequate  surgical  hemostasis.  Epidural  catheter  should
be  removed  before  restarting  LMWH  regimen.  If  the  tech-
nique  of  continuous  analgesia  is  chosen,  catheter  may
be  maintained  until  the  morning  of  the  day  following
surgery, provided  that  removed  before  the  ﬁrst  dose  of
LMWH,  which  may  be  administered  2  hours  after  catheter
removal  (D).6taking  anticoagulants  9
itamin K  antagonists (coumarins)
itamin  K  antagonists  include  acenocoumarol,  phenpro-
oumon, and  warfarinas.  These  drugs  inhibit  the  gamma-
arboxylation synthesis  of  vitamin  K-dependent  factors  (II,
II,  IX,  X)  and  C  and  S  proteins,  which  makes  them  unable
o bind  phospholipid  in  platelet  membranes  during  coagu-
ation. Prothrombin  time  (PT)  and  international  normalized
atio (INR)  are  tests  commonly  used  to  monitor  these  drugs
nd reﬂect  the  plasma  activity  of  three  (II,  VII,  and  X)  of
he four  clotting  factors.  Clinical  experiences  suggest  that
he 40%  activity  level  of  each  factor  is  adequate  for  nor-
al hemostasis,  or  near  normal.80 INR  of  1.5  is  associated
ith the  40%  activity  of  factor  VII.81 Because  factor  VII
as a shorter  half-life  (about  6  hours),  the  initial  increase
f INR  when  coumarin  anticoagulants  are  used  reﬂects  the
oss of  factor  VII  activity.  However,  these  drugs  therapeu-
ic effect  is  more  dependent  on  the  reduction  of  factors
I and  X,  which  have  half-lives  relatively  longer,  60  to
2 hours  and  24  to  36  hours,  respectively.  After  warfarin  dis-
ontinuation, factor  II  is  the  latest  to  normalize.82 Thus,
fter drug  discontinuation,  INR  may  return  to  near  nor-
al values  due  to  the  activity  restoration  of  factor  VII.
owever, factors  II  and  X  may  not  have  been  restored  to
ormal hemostatic  levels.81 Its  anticoagulant  effect  can  be
ffectively prevented  by  vitamin  K,  fresh  frozen  plasma  or
rothrombin complex  concentrate  (II,  VII,  IX,  and  X  factors)
dministration.2
Although  the  ASRA  has  recommended  epidural  catheter
emoval with  INR  less  than  1.5,  this  value  has  been  con-
idered as  conservative.  Reports  show  epidural  catheter
emoval with  INR  higher  and  uneventful.83,84 If  it  occurs  in
he ﬁrst  48  hours  of  medication  use,  it  is  likely  that  there
re adequate  levels  of  clotting  factors  activity,  particularly
I and  X  factors.  Beyond  this  period,  all  vitamin  K-dependent
lotting factors  will  be  affected.  There  was  no  reported  case
f  spinal  hematoma  in  11,235  patients  receiving  epidural
nalgesia after  total  knee  arthroplasty,  and  treated  with
arfarin (5-10  mg)  started  the  night  before  the  procedure.
pidural catheters  were  removed  48  hours  postoperatively.
ean INR  at  recession  time  of  was  1.5  (0.9-4.3).  INR  was
ess than  1.5  in  approximately  40%  of  cases.  These  series
uggest that  not  only  the  INR  value  should  be  considered
uring epidural  catheter  management,  but  also  the  dura-
ion of  therapy  with  warfarin,  and  that  a  prolonged  time  for
ore than  48  hours  may  represent  signiﬁcant  increased  risk
f hematoma.84
Perioperative  management  of  patients  on  warfarin
emains controversial.  Recommendations  are  based  on  drug
harmacology, clinically  relevant  levels,  and  deﬁciency  of
itamin K-dependent  clotting  factors,  case  series,  and  spinal
ematoma reports.6
ecommendations
.  Neuraxial  blockade  should  only  be  performed  4-5  days
after  drug  discontinuation,  conﬁrmed  by  normal  INR.
Consider  that  in  the  ﬁrst  three  days  after  drug  discon-
tinuation,  coagulation  (reﬂected  primarily  by  levels  of
factors  II  and  X)  may  not  be  adequate  for  hemostasis,
despite a  decrease  in  INR  (indicating  a  return  of  factor
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VII  activity).  Appropriate  levels  of  factors  II,  VII,  IX,  and
X  may  not  be  present  until  INR  is  within  the  reference
range (B);6
.  If  warfarin  thromboprophylaxis  was  initiated  postopera-
tively,  remove  neuraxial  catheter  with  an  INR  less  than
1.5.  This  value  was  obtained  from  studies  that  correlated
hemostasis with  clotting  factor  activity  levels  greater
than  40%.  In  these,  neurological  monitoring  must  be  kept
for  least  24  hours  after  catheter  removal  (D);6
.  When  replacing  coumarin  by  LMWH  or  UFH  preopera-
tively,  consider  the  UFH  and  LMWH  recommendations  for
neuraxial  block  (D);2
.  If  patient  is  on  low  doses  of  warfarin  during  epidural
analgesia,  INR  monitoring  should  be  done  daily  (D).6
actor Xa inhibitors
ondaparinux  (Arixtra®)
ondaparinux  is  a  synthetic  selective  pentasaccharide  that
ndirectly inhibits  factor  Xa.  Unlike  the  LMWH,  it  has
o effect  on  factor  IIa  (thrombin).  Platelet  aggregation
s unaffected.3 This  compound  has  approximately  100%
ioavailability after  subcutaneous  administration  and  half-
ife of  elimination  of  18-21  hours,  primarily  by  the  kidneys.
alf-life is  prolonged  to  36-42  hours  when  creatinine  clear-
nce is  less  than  50  mL.min-1,  and  is  contraindicated  in
atients with  clearance  less  than  30  mL.min-1.85 Prophylac-
ic dose  is  2.5  mg  via  subcutaneous  rout  once  daily.
Fondaparinux  is  usually  administered  6-12  hours  after
urgery, as  its  preoperative  use  may  increase  the  risk  of  sur-
ical bleeding  without  improving  antithrombotic  efﬁcacy.86
ecause  it  is  used  postoperatively,  there  are  no  problems
ith single  puncture  neuraxial  anesthesia.  However,  if  the
atheter is  inserted,  it  should  be  removed  only  in  the
bsence of  fondaparinux  plasma  levels.  The  recommen-
ations for  epidural  catheter  management  in  patients  on
ondaparinux are  based  on  the  conditions  used  in  the  study
y Singelyn  et  al.87 This  study  evaluated  5,387  patients,  of
hom 1,428  underwent  regional  anesthesia,  and  the  single
ose of  fondaparinux  the  night  before  catheter  removal  was
mitted. Thus,  the  research  team  ensured  an  interval  of
6 hours  between  the  last  dose  and  catheter  removal  and
2 hours  between  catheter  removal  and  the  subsequent  dose
f fondaparinux.  There  was  no  case  of  spinal  hematoma  and
o increased  risk  of  DVT.87
According  to  the  American  College  of  Chest  Physicians
ACCP), even  with  two  reported  cases  of  HIT  with  fonda-
arinux, its  use  in  patients  with  a  history  of  HIT  is  suggested
s an  option  to  UFH  or  LMWH.88
ecommendations
.  At  prophylactic  dose  (2.5  mg)  fondaparinux  may  be  used
in  postoperative  with  atraumatic  neuraxial  anesthesia.
If used,  epidural  catheter  should  be  removed  only  after
36  hours  of  the  last  dose  and  the  subsequent  dose  admin-
istered  only  after  12  hours  of  removal  (D);3
.  Neuraxial  aneshesia  is  contraindicated  when  fonda-
parinux  (5-10  mg.day-1)  is  used  in  therapeutic  doses  due
b
i
n
aN.M.  Fonseca  et  al.
to  the  risk  of  unpredictable  residual  effect  in  the  body
(D).3
ivaroxaban (Xarelto®)
ivaroxaban  is  a  selective  inhibitor  of  factor  Xa.  It  is  orally
dministered and  approved  for  DVT  prevention  after  total
nee and  hip  replacement  surgery.  Treatment  is  initiated
-8 hours  after  surgery;  with  a  single  dose  of  10  mg,  peak
lasma levels  are  achieved  in  2-4  hours.  Studies  show  better
fﬁcacy compared  to  enoxaparin  for  thromboprophylaxis,89
s  well  as  compared  to  heparins  and  vitamin  K  antagonists
or treating  DVT.90
Rivaroxaban  has  a half-life  of  5-9  hours,  is  poorly  inﬂu-
nced by  renal  function  (33%  clearance  occurs  via  kidneys),
s it  also  has  hepatic  clearance.  However,  in  the  elderly,  the
alf-life may  be  prolonged  to  11-13  hours.3
Rivaroxaban  prolongs  aPTT  and  HepTest,  but  these  tests
re not  recommended  to  evaluate  the  drug  anticoagulant
ffect.91 Prothrombin  time  (PT)  is  inﬂuenced  by  rivarox-
ban in  a  dose  dependent  manner,  with  close  correlation
ith plasma  concentrations,92 and  should  be  measured  in
econds and  not  by  IRN.  However,  routine  monitoring  is  not
onsidered necessary.  Similar  to  most  new  anticoagulants,
ivaroxaban cannot  be  antagonized.2
ecommendations
.  Due  to  the  lack  of  prospective  studies,  an  interval
greater than  two  half-lives  of  elimination  is  recom-
mended (24  hours)  to  perform  neuraxial  block  or  epidural
catheter  removal;28
.  Because  peak  plasma  level  occurs  within  2-4  hours,  the
subsequent  dose  should  be  given  4-6  hours  after  catheter
removal  (D);28
.  If  there  is  traumatic  puncture  with  bleeding,  rivaroxaban
should  be  delayed  for  24  hours  (D).91
pixaban (Eliquis®)
pixaban  is  a  direct  factor  Xa  inhibitor,  administered  orally.
t has  60%  bioavailability  and  does  not  require  biotrans-
ormation for  activation.93 In  contrast  with  vitamin  K
ntagonists, apixaban  does  not  interact  with  food.  Peak
lasma levels  are  reached  in  3  hours,  half-life  is  about
2 hours  (10-15  hours),  and  two  daily  doses  are  required.93,94
here  is  no  need  for  routine  coagulation  monitoring.  Kidneys
liminate only  25%  and  the  hepatic  and  biliary  metabolisms
liminate 75%,  excreted  via  the  bowel.
Randomized  studies  have  shown  the  efﬁcacy  and  safety
f apixaban  after  knee  and  hip  replacement  surgeries.95--97
valuation  of  18,201  individuals  with  atrial  ﬁbrillation,
hich compared  apixaban  with  warfarin,  showed  that  apix-
ban was  superior  in  thromboprophylaxis,  with  low  risk  of
leeding and  lower  mortality  rate.98 Based  on  these  stud-
es, apixaban  is  likely  to  be  approved  for  anticoagulation  in
on-valvular atrial  ﬁbrillation  and  thromboprophylaxis  in  hip
nd knee  surgeries.
ents  
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NSBA  Recommendations  for  regional  anesthesia  safety  in  pati
Recommendations
1.  Use  the  same  rules  for  new  anticoagulants;  i.e.,  interval
of  two  half-lives  of  elimination  (20-30  hours)  to  perform
neuraxial  block  or  remove  epidural  catheter  (D);3
2.  After  catheter  removal,  restart  apixaban  within  4-6  hours
(D).3
Thrombin inhibitors
Dabigatran  (Pradaxa®)
Dabigatran  is  a  new  thrombin  reversible  inhibitor  orally
administered and  recently  approved  for  DVT  prophylaxis
in patients  undergoing  hip  or  knee  replacement  surgery.99
Dabigatran  is  administered  as  the  prodrug  (dabigatran  etex-
ilate), which  is  converted  to  dabigatran  by  plasma  esterases.
This compound  has  a  half-life  of  12-17  hours,  eliminated
mainly by  the  kidney,  and  cannot  be  antagonized.  After
administration, peak  plasma  levels  are  reached  in  2-4  hours.
Effects  of  continuous  use  may  persist  for  5-7  days,  depending
on renal  function.1
Treatment  is  initiated  1-4  hours  after  surgery  at  doses
ranging from  75  mg  (creatinine  clearance  30-50  mL.min-1)
to 110  mg  (normal  renal  function).  Dosage  is  escalated
to 150  mg  to  220  mg  on  subsequent  days.  Dabigatran  pro-
longs aPTT  without  linear  effect.  Thrombin  time  (TT)
is particularly  sensitive  and  reference  for  anticoagula-
tion management,  with  linearity  between  dose-response
in therapeutic  concentrations.1 Anticoagulation  reversal  is
theoretically possible  by  administration  of  recombinant  fac-
tor VIIa,  although  not  clinically  tested.100
The  effectiveness  of  dabigatran  (220  mg)  for  DVT  pre-
vention is  compared  to  that  of  enoxaparin  (40  mg.day-1)
and without  increased  bleeding.101 Preliminary  studies  of
dabigatran and  neuraxial  block  were  conducted  with  epidu-
ral catheter  removal  4-6  hours  before  the  ﬁrst  dose.  There
is no  study  of  patients  on  dabigatran  and  use  of  epidural
catheters.
Recommendations
1.  Because  DVT  prophylaxis  with  dabigatran  is  initiated
postoperatively, there  is  no  limitation  to  simple  neuraxial
block  (D);3
2.  Dabigatran  discontinuation  should  be  at  least  seven  days
before  neuraxial  block  to  allow  return  to  normal  coagu-
lation  (D);1
3.  The  half-live  of  12-17  hours  suggests  a  34  hours  inter-
val  between  the  last  dose  and  catheter  management  or
removal.  However,  the  manufacturer’s102 recommenda-
tion is  to  avoid  epidural  catheter  in  patients  on  this  drug
and  that  the  ﬁrst  dose  should  be  administered  at  least
2  hours  after  catheter  removal  (D);3
4.  However,  because  plasma  level  can  be  reached  in  2  hours,
it  is  prudent  to  observe  a  minimum  interval  of  6  hours
after  catheter  removal  to  start  drug  administration  (D).2
C
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rgatroban (Argatra®)
rgatroban  is  a direct  thrombin  reversible  inhibitor  that
inds to  the  different  forms  of  thrombin.103,104 It  is  indicated
or patients  with  thrombosis  associated  with  heparin-
nduced thrombocytopenia  (HIT)  by  the  lack  of  interaction
ith platelet  factor  4  (PF4).2
Argatroban  is  administered  by  continuous  IV  infusion  and
liminated exclusively  by  the  liver,  and  may  be  used  in  renal
ailure. The  dose  of  0.5-2  g.kg.min-1 is  adjusted  to  maintain
PTT within  1.5  to  3  of  the  normal  value.  In  patients  with
ood liver  function,  aPTT  normalization  occurs  2-4  hours
rom the  end  of  infusion  due  to  the  short  half-life  of  35-
5 minutes.105
ecommendations
.  The  insertion  of  spinal/epidural  needle/catheter  should
be  made  at  least  4  hours  after  drug  discontinuation.  The
drug  reintroduction  time  after  the  blockade  or  catheter
removal  is  2  hours  and  always  excluded  residual  coagu-
lant  effect  by  aPTT  and  ACT  measurements  (D);2
.  If  the  patient  is  under  argatroban  therapy  due  to  diag-
nosis  of  acute  HIT,  treatment  should  not  be  discontinued
because of  the  risk  of  thromboembolism  and,  therefore,
blockade  is  contraindicated  (D).2
esirudin (Iprivask®) e lepirudin (Reﬂudan®)
ecombinant  hirudins  (lepirudin  and  desirudin)  are  from
he ﬁrst  generation  of  direct  thrombin  inhibitors  and  are
arenterally administered.  They  have  no  interaction  with
latelet factor  4  (PF4)  and,  therefore,  do  not  trigger
eparin-induced thrombocytopenia  (HIT).  Desirudin  is  indi-
ated  for  DVT  prophylaxis  and  lepirudin  for  DVT  treatment
f patients  with  history  of  HIT.3
Both  lepirudin  and  desirudin  have  half-lives  of  1.3-
 hours,  but  it  increases  signiﬁcantly  in  renal  failure.  Due
o the  potential  risk  of  bleeding,  the  anticoagulant  effect  of
irudin should  be  routinely  monitored  with  aPTT  or  ecarin
lotting time  (ECT).106
ecommendations
.  In  patients  with  normal  renal  function,  wait  8-10  hours
from  last  dose  to  perform  neuraxial  block  with  or  without
epidural  catheter  installation  (D);3
.  In  patients  with  normal  renal  function,  wait  8-10  hours
from  last  dose  to  remove  catheter  (A);3
.  Wait  2-4  hours  to  restart  these  drugs  after  puncture  or
epidural  catheter  removal  (D);3
.  Absence  of  residual  anticoagulant  effect  should  always
be  conﬁrmed  by  determining  aPTT  and  ECT  (D).3
euraxial block and laboratory testsurrent  guidelines  and  consensus  state  that  neuraxial  block
hould not  be  performed  in  patients  with  thrombocytopenia;
owever, none  of  them  determine  the  minimum  limit  of
latelets number  to  perform  neuraxial  block.4
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Platelet  function  appears  to  be  more  important  than
he isolated  number  of,  platelet.107 Researchers  suggest  a
latelet count  greater  than  50,000.mm-3 with  preserved
unction as  acceptable,  while  a  platelet  count  greater  than
00,000.mm-3 is  acceptable  without  considering  evaluation
est of  platelet  function.108,109
A  recent  study  reported  that  in  the  absence  of  risk
actors, platelet  count  >  80,000.mm-3 is  considered  safe
o perform  spinal/epidural  blocks  and  platelet  count  >
0,000.mm-3 to  perform  simple  lumbar  puncture.110
Regarding  secondary  hemostasis,  the  40%  activity  level
f each  factor  is  adequate  or  near  normal  for  normal
emostasis.80 INR  of  1.5  is  associated  with  the  40%  activity  of
actor VII.  Bleeding  may  occur  if  the  level  of  any  coagulation
actor is  reduced  to  20-40%  of  its  normal  value.81
ecommendations
.  Epidural  or  spinal  blocks,  in  the  absence  of  risk  factors  for
bleeding,  may  be  performed  with  platelet  count  above
80,000.mm-3 (D);110
.  INR  <1.5  is  considered  safe  to  perform  neuraxial  blocks
(D).6
eripheral nerve blocks and anticoagulants
lthough  spinal  hematoma  is  the  most  important  hemor-
hagic complication  of  regional  anesthesia  because  of  the
atastrophic nature  of  bleeding  into  a  restricted  and  non-
ompressible space,  the  associated  risk  after  plexus  and
eripheral nerve  blocks  remains  undeﬁned.
The  presence  of  hematoma  may  increase  morbidity  and
ortality, and  there  are  reported  cases  involving  retroperi-
oneal hematoma  after  lumbar  plexus  block  with  the  use
f enoxaparin  or  clopidogrel.  In  one  of  these  reports,  the
atheter inserted  into  the  lumbar  plexus  was  removed
.5 hours  after  the  last  dose  of  heparin.111,112
Although  most  of  the  cases  have  evolved  without  neuro-
ogical damage,  there  was  extension  of  the  hospital  stay,
ith injury  and  patient  dissatisfaction,  as  well  as  need
or transfusion  of  packed  red  blood  cells.  Some  showed
eﬁcits engines  and  sensitives,  renal  failure  and  death  by
leeding.111--113
The  German  Society  of  Anesthesiology  and  Intensive
are Medicine  adopts  the  same  recommendations  for  neu-
axial, peripheral  nerve,  and  plexus  blocks  in  patients  on
ntithrombotic drugs.114 The  Austrian  Society  differenti-
tes neuraxial  blocks  from  deep  or  superﬁcial  peripheral
locks.115 These  latter,  similar  to  axillary  brachial  plexus,
emoral nerve,  and  distal  sciatic  blocks,  may  be  performed
ith the  use  of  ASA  and  anticoagulants.115
With  the  increasing  use  of  ultrasound  to  aid  peripheral
erve and  plexus  blocks,  the  number  of  complications,  such
s vascular  puncture,  decreased  because  of  the  dynamic
isualization of  structures  adjacent  to  the  nerve  to  be
locked.116 Thus,  evidence  probably  will  demonstrate  the
ctual decrease  in  complication  rates  with  this  technique
nd, therefore,  recommend  the  relatively  safe  use  of  periph-
ral nerve  blocks  guided  by  ultrasound  in  anticoagulated
atients.N.M.  Fonseca  et  al.
ecommendations
.  Respect  the  interval  between  LMWH  administration  and
insertion/removal  of  catheters  similar  to  those  used  for
neuraxial  blocks  (D);3
.  Do  not  remove  any  catheter  in  the  period  of  anticoagu-
lant greatest  activity  (D);3
.  Because  morbidity  is  associated  with  retroperitoneal
hematoma, paravertebral  or  lumbar  plexus  blocks  have
the  same  recommendations  used  in  neuraxial  blocks
(D).111
.  Superﬁcial  blocks,  such  as  axillary,  femoral  or  distal  sci-
atic,  may  be  performed  with  the  use  of  anticoagulation
or antiplatelet  therapy  (D).111
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